liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The risk of HCV RNA contamination in serology screening instruments with a fixed needle for sample transfer.
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Health Sciences.
Örebro University, Sweden.
Show others and affiliations
2014 (English)In: Journal of Clinical Virology, ISSN 1386-6532, E-ISSN 1873-5967, Vol. 60, no 2, 172-173 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Hepatitis C diagnostics involve antibody screening and confirmation of current infection by detection of HCV RNA positivity. In screening instruments with fixed pipetting needle, there is a risk of sample carry-over contamination.

OBJECTIVES: The aim of this study was to evaluate the risk of such contamination in a proposed clinical setting.

STUDY DESIGN: In the present study, known HCV RNA positive (n=149) and negative (n=149) samples were analysed by anti-HCV Abbott in an Architect instrument in an alternating fashion in order to test for contamination.

RESULTS: In subsequent retesting of the previously HCV RNA-negative samples, six samples (4%) were positive by the Cobas Taqman assay with a maximum level of 33IU/mL. The results show that there is a risk for transfer of HCV in the Architect instrument but they also show that the levels of HCV RNA observed are low.

CONCLUSIONS: We conclude that complementary HCV RNA testing on samples identified as anti-HCV positive by screening can be recommended because the complementary results are reliable in the majority of cases when either HCV RNA is negative or HCV RNA is positive with a level >1000IU/mL. In a minority of cases, with low HCV RNA after anti-HCV antibody screening, cross-contamination should be suspected and a new sample requested for HCV RNA testing. This strategy would reduce the need for obtaining a new sample from the vast majority of patients with a newly discovered HCV antibody positivity.

Place, publisher, year, edition, pages
2014. Vol. 60, no 2, 172-173 p.
National Category
Microbiology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-107297DOI: 10.1016/j.jcv.2014.03.011ISI: 000335738000016PubMedID: 24735614OAI: oai:DiVA.org:liu-107297DiVA: diva2:723212
Available from: 2014-06-10 Created: 2014-06-10 Last updated: 2017-12-05

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Åkerlind, BrittCardell, KristinaSerrander, Lena

Search in DiVA

By author/editor
Åkerlind, BrittCardell, KristinaSerrander, Lena
By organisation
Division of Microbiology and Molecular MedicineFaculty of Health SciencesDepartment of Infection ControlDepartment of Infectious Diseases
In the same journal
Journal of Clinical Virology
Microbiology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 157 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf